Klinisyenler İçin Tiroglobulin Ölçüm Yöntemleri

Öz

Son yıllarda differansiye tiroid kanseri görülme sıklığı belirgin şekilde artmaktadır. Tiroglobulin sadece tiroid follikül hücresinde sentezlenmesi ve dolaşıma verilmesi DTK’li hastaların takibinde tümör belirteci olarak kullanılmasını sağlamıştır. Günümüzde standart takip, Tg ölçümü ve boyun ultrasonografisini içermektedir. Uygun endikasyonda tüm vücut iyot taraması yapılabilir. Klinik rehberlerde küçük odakların saptanmasında suboptimal sensitiviteye sahip Tg ölçümlerin kullanılması durumunda ekzojen veya endojen TSH uyarımı sonrası Tg ölçümü önerilmektedir. Bununla birlikte günümüzde yüksek sensitivite oranlarına sahip metotların kullanılmasıyla, TSH uyarımına gerek olmadan çok düşük konsantrasyonlardaki Tg’nin doğru saptanmasını, bazı dezavantajlarına rağmen, sağlamaktadır. Tg’nin hangi yöntemle bakıldığı, anti tg ve heterofil antikor varlığında olabilecek değişikliği bilerek kullanılması klinisyen için önemlidir. Klinisyenler tarafından bu yeni metotların avantaj ve dezavantajının bilinmesi, hem serum hem de Tg–yıkama sonuçlarının doğru değerlendirilerek, hastaya gereksiz tetkik yapılmasını önleyecektir.

Anahtar Kelimeler

• Tiroglobulin
• Tiroglobulin ölçüm yöntemleri
• İnterferans

Thyroglobulin Measurement Methods for Clinicians

Öz

The frequency of differentiated thyroid cancer has increased markedly in recent years. Thyroglobulin is synthesized only in the thyroid follicle cell and given to the circulation, it has been used as a tumor marker in the follow-up of patients with DTC. Currently standart follow up DTC comprises Tg measurement and neck ultrasound. In adequate indication whole body radioiodine scan make up. Clinical guidelines recommended that, measurement of Tg after stimulation by endogenous or exgogenous TSH to detect occult disease focus when suboptimal sensitivity of Tg assays used. However, nowadays, highly sensitivity methods used with despite of disadvantage, without the need TSH stimulation, at very low Tg concentrations ensured correct detection. In which methods used for Tg assays and possible change in the presence of thyroglobuline and heterophile antibody very important for clinicians. This new methods to be know the advantages and disadvantages by clinicians, the results of serum and Tg washout evaluated corretly, prevented the patient’s unnecessary investigation.

Anahtar Kelimeler

• Thyroglobulin
• Thyroglobulin Measurement methods
• İnterferance

Kaynakça

1. 1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214.
2. 2. Grebe SKG. Diagnosis and management of thyroid carcinoma: focus on serum thyroglobulin. Expert Review of Endocrinology & Metabolism 2009;4:25–43.
3. 3. Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol. 2003;58:138–40.
4. 4. Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clinical Chemistry and Laboratory Medicine 2008;46:1067–73.
5. 5. Zo¨phel K, Wunderlich G, Smith BR. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 2003;13:861–5.
6. 6. Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clinical Endocrinology 2007; 67:434–41.
7. 7. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism 2007;92:82–7.
8. 8. Giovanella L, Clark PM, Duntas LC, Elisei R, Feldt-Rasmussen U, Leenhardt L et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. European Journal ofEndocrinology 2014:171;33–46.

9. 9. Spencer CA, Takeuchi M, Kazarosyan M, Wang C,Guttler RB, Singer PA et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121–27.
10. 10. Diessl S, Holzberger B, Ma¨der U, Grelle I, Smit JW, Buck AK et al. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clinical Endocrinology 2012;76:586–92.
11. 11. Verburg FA, Mader U, Tanase K, Thies ED, Diessl S, Buck AK et al. Life expectancy is reduced in differentiated thyroid cancer patients R45 years old with extensive local tumour invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. Journal of Clinical Endocrinology and Metabolism. 2013;98:172–80.
12. 12. Pacini F. Follow-up of differentiate thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2002;29:492–6.
13. 13. Giovanella L, Feldt-Rasmussen U, Verburg FA, Grebe SK, Plebani M, Clark PM. Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges. Clin Chem Lab Med 2015;53:1301–14.
14. 14. Alicia Algeciras-Schimnich. Thyroglobulin measurement in the management of patients with differentiated thyroid cancer. Critical Reviews in Clinical Laboratory Sciences 2018;55:205-18.
15. 15. Spencer C, Fatemi S. Thyroglobulin antibody (TgAb) methods –Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Practice & Research Clinical Endocrinology & Metabolism. 2013;27:701–12.
16. 16. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-rasmussen U, Henry JF et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3–126.
17. 17. Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (secondgeneration) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab 2014;99:4589–99.
18. 18. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566–75.
19. 19. Van Herle AJ, Uller RP, Matthews NI. Radioimmunoassay for measurement of thyroglobulin in human serum. J Clin Invest 1973;52:1320–7.
20. 20. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P,Travaglı JP et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960–7.
21. 21. Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2011;96:1283–91.
22. 22. Spencer C, LoPresti J, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes 2014;21:394–404.
23. 23. Schneider AB, Pervos R. Radioimmunoassay of human thyroglobulin: effect of antithyroglobulin autoantibodies. J Clin Endocrinol Metab 1978;47:126–37.
24. 24. Weightman DR, Mallick UK, Fenwick JD. Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma: correlation with clinical outcome after 3 years of follow-up. Cancer 2003;98:41–7.
25. 25. Jahagirdar VR, Strouhal P, Holder G, Gama R, Singh BM. Thyrotoxicosis factitia masquerading as recurrent Graves’ disease: endogenous antibody immunoassay interference, a pitfall for the unwary. Ann Clin Biochem 2008;45:325–7.
26. 26. Clarke NJ, Zhang Y, Reitz RE. A novel mass spectrometry- based assay for the accurate measurement of thyroglobulin from patient samples containing antithyroglobulin autoantibodies. J Investig Med 2012;60:1157–63.
27. 27. Netzel BC, Grebe SK, Carranza Leon BG. Thyroglobulin (Tg) testing revisited: Tg assays, TgAb assays, and correlation of results with clinical outcomes. J Clin Endocrinol Metab 2015;100:1074–83.
28. 28. Spencer C, Fatemi S, Singer P, Nicoloff J, LoPresti J. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin- stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid. 2010;20:587–95.
29. 29. Giovanella L, Treglia G, Sadeghi R, Trimboli P,Ceriani L,Verburg FA. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab 2014;99:440–7.
30. 30. Haugen BR. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer 2017;123:372–81.
31. 31. Pacini F, Sabra MM, Tuttle RM. Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer. Thyroid 2011;21:691–2.
32. 32. Piechaczyk M, Bouanani M, Salhi SL, Baldet L,Bastide M, Pau B. Antigenic domains on the human thyroglobulin molecule recognized by autoantibodies in patients’ sera and by natural autoantibodies isolated from the sera of healthy subjects. Clin Immunol Immunopathol 1987;45:114–21.
33. 33. Ruf J, Carayon P, Lissitzky S. Various expressions of a unique anti-human thyroglobulin antibody repertoire in normal state and autoimmune disease. Eur J Immunol 1985;15:268–72.
34. 34. Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid 2013;23:1211-25.
35. 35. Anderson NL, Anderson NG, Haines LR, Hardia DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 2004;3:235–44.
36. 36. Kushnir MM, Rockwood AL, Roberts WL, Abraham D, Hoofnagle AN, Meikle AW. Measurement of thyroglobulin by liquid chromatography- tandem mass spectrometry in serum plasma in the presence of antithyroglobulin antibodies. Clin Chem 2013;59:982-90.
37. 37. Netzel BC, Grebe SK, Algeciras-Schimnich A. Usefulness of a thyroglobulin liquid chromatographytandem mass spectrometry assay for evaluation of suspected heterophile interference. Clin Chem 2014;60:1016–18.
38. 38. Akdi A, Perez G, Pastor S, Castell J, Biarnes J, Marcos R, et al. Common variants of the thyroglobulin gene are associated with differentiated thyroid cancer risk. Thyroid 2011;21:519-25.
39. 39. Vono-Toniolo J, Kopp P. Thyroglobulin gene mutations and other genetic defects associated with congenital hypothyroidism. Arq Bras Endocrinol Metabol 2004;48:70-82.
40. 40. Bertaux F, Noel M, Malthiéry Y, Fragu P. Demonstration of a heterogeneous transcription pattern of thyroglobulin mRNA in human thyroid tissues. Biochem Biophys Res Comm 1991;178:586-92.
41. 41. Azmat U, Porter K, Senter L, et al. Thyroglobulin liquid chromatography-tandem mass spectrometry has a low sensitivity for detecting structural disease in patients with antithyroglobulin antibodies. Thyroid 2017;27:74–80.
42. 42. Weigle WO, High GJ. The behavior of autologous thyroglobulin in the circulation of rabbits immunized with either heterologous or altered homologous thyroglobulin. J Immunol 1967;98:1105-14.
43. 43. Feldt Rasmussen U, Petersen PH, Date J, Madsen CM. Sequential changes in serum thyroglobulin (Tg) and its autoantibodies (TgAb) following subtotal thyroidectomy of patients with preoperatively detectable TgAb. Clin Endocrinol (Oxf) 1980;12:29-38.
44. 44. van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and antiinfliximab in responders and nonresponders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007;66:253-6.
45. 45. Netzel BC, Grant RP, Hoofnagle AN, Rockwood AC,Grebe SKG. First steps toward harmonization of LC-MS/MS thyroglobulin assays. Clin Chem 2016;62:297- 9.
46. 46. Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab 2014;99:4589-99.
47. 47. Boldarine VT, Maciel RM, Guimaraes GS, Nakabashi CC, Camacho CP, Andreoni DM, et al. Development of a sensitive and specific quantitative reverse transcription-polymerase chain reaction assay for blood thyroglobulin messenger ribonucleic acid in the follow-up of patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2010;95:1726-33.
48. 48. Hu S, Ewertz M, Tufano RP, Brait M, Carvalho AL, Liu D, et al. Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. J Clin Endocrinol Metab 2006;91:98-104.
49. 49. Milas M, Shin J, Gupta M, Novosel T, Nasr C, Brainard J, et al. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann Surg. 2010;252:643-51.
50. 50. Roitt IM, Doniach D, Campbell PN, Hudson RV. Auto-an¬tibodies in Hashimoto's disease (lymphadenoid goitre). Lancet 1956;271:820-1.
51. 51. Rose NR, Witebsky E. Studies on organ specificity. V. Changes in the thyroid glands of rabbits following active immunization with rabbit thyroid extracts. J Immunol 1956;76:417-27.
52. 52. Barin JG, Talor MV, Sharma RB, Rose NR, Burek CL. Io¬dination of murine thyroglobulin enhances autoimmune reactivity in the NOD.H2 mouse. Clin Exp Immunol 2005;142:251-9.
53. 53. Li Y, Teng D, Shan Z, Teng X, Guan H,Yu X et al. Antithyroperoxidase and anti¬ thyroglobulin antibodies in a five-year follow-up survey of populations with different iodine intakes. J Clin Endo¬crinol Metab 2008;93:1751-7.
54. 54. Fröhlich E, Wahl R. Thyroid autoimmunity: role of an¬ti-thyroid antibodies in thyroid and extra-thyroidal dis¬eases. Front Immunol 2017;8:521.
55. 55. Gentile F, Ferranti P, Mamone G, Malorni A, Salvatore G. Identification of hormonogenic tyrosines in fragment 1218-1591 of bovine thyroglobulin by mass spectrometry. Hormonogenic acceptor TYR-12donor TYR-1375. J Biol Chem. 1997;272:639-46.
56. 56. Jo K, Lim DJ. Clinical implications of anti-thyroglobulin antibody measurement before surgery inthyroid cancer. Korean J Intern Med 2018;33:1050-7.
57. 57. Gorges R, Maniecki M, Jentzen W, Shue SY, Mann K, Bockisch A et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005;153:49–55.
58. 58. Hollowell JG, Staehling NW, Flanders WD, Hannon WH,Gunter EW, Spencer CA et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–99.
59. 59. Okosieme OE, Evans C, Moss L,Parkes AB, Premawardhara LDK, Lazarus JH. Thyroglobulin antibodies in serum of patients with differentiated thyroid cancer: relationship between epitope specificities and thyroglobulin recovery. Clin Chem 2005;51:729–34.
60. 60. Rosario PW, Maia FF, Fagundes TA, Vasconcelos FP, Cardosa LD, Purisch S. Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance. Arq Bras Endocrinol Metabol 2004;48:487–92.
61. 61. Verburg FA, Hartmann D, Grelle I, Giovenella L, Buck AK, Reiners C. Relationship, between antithyroglobulin autoantibodies and thyroglobulin recovery rates using different thyroglobulin concentrations in the recovery buffer. Horm Metab Res 2013;45:728–35.
62. 62. Katrangi W, Grebe SKG, Algeciras-Schimnich A. Analytical and clinical performance of thyroglobulin autoantibody assays in thyroid cancer follow-up. Clin Chem Lab Med 2017;55:1987–94.
63. 63. Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ Paschke R, Rago T. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J 2013;2:147–59.
64. 64. Gharib H, Papini E, Garber JR, Daniel SG, Herrell RM,hegedis L et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for clinical practice for the diagnosis and management of thyroid nodules–2016 update. Endocr Pract 2016;22:622–39.
65. 65. La’ulu SL, Slev PR, Roberts WL. Performance characteristics of 5 automated thyroglobulin autoantibody and thyroid peroxidase autoantibody assays. Clin Chim Acta 2007;376:88–95.
66. 66. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008;54:1796–804.
67. 67. Latrofa F, Ricci D, Montanelli L, Rocch R,Piaggi P,Sisiti E et al. Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin. J Clin Endocrinol Metab. 2012;97:2380–7.
68. 68. Thomas D, Liakos V, Vassiliou E, Hatzimarkou F,Tsatsoulis A,Kaldrimides P. Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation. J Endocrinol Invest. 2007;30:173–80.
69. 69. Kim WG, Yoon JH, Kim WB, Kim YT, Kim YE,Kim JY et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2008;93:4683–9.
70. 70. Pacini F, Mariotti S, Formica N, Elisei R,Anelli S, Capotorti E et al. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol 1988;119: 373–80.
71. 71. Seo JH, Lee SW, Ahn BC, Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/ CT. Clin Endocrinol (Oxf) 2010;72:558-63.
72. 72. Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 2002;57:215-21.
73. 73. Feldt-Rasmussen U, Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, et al. Thyroglobulin autoantibodies as surrogate biomarkers in the management of patients with differentiated thyroid carcinoma. Curr Med Chem 2014;21:3687-92.
74. 74. Weigle WO, High GJ. The behavior of autologous thyroglobulin in the circulation of rabbits immunized with either heterologous or altered homologous thyroglobulin. J Immunol 1967;98:1105–14.
75. 75. Feldt-Rasmussen U, Petersen PH, Date J. Sequential changes in serum thyroglobulin (Tg) and its autoantibodies (TgAb) following subtotal thyroidectomy of patients with preoperatively detectable TgAb. Clin Endocrinol 1980;12:29–38.
76. 76. Verburg FA, Lips CJ, Lentjes EG, de Klerk JM. Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it? Br J Cancer 2004;91:200–4.
77. 77. Giovanella L, Keller F, Ceriani L, Tozzoli R. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med. 2009;47:952–4.
78. 78. Preissner CM, O’Kane DJ, Singh RJ, Morris JC, Grebe SKG. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003;88:3069–74.
79. 79. Spencer C, LoPresti J, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes 2014;21:394-404.
80. 80. Schulz R, Bethauser H, Stempka L, Heilig B, Moll A, Hufner M. Evidence for immunological differences between circulating and thyroid tissue-derived thyroglobulin in men. Eur J Clin Invest 1989;19:459-63.
81. 81. Pacini F, Fugazzola L, Lippi F, Centoni R,Miccoli P, Elisei R et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab 1992;74:1401–04.
82. 82. Baskin HJ. Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. Thyroid 2004;14:959–63.
83. 83. Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. J Clin Endocrinol Metab 2014;99:1970–82.
84. 84. Borel AL, Boizel R, Faure P. Significance of low levels of thyroglobulin in fine needle aspirates from cervical lymph nodes of patients with a history of differentiated thyroid cancer. Eur J Endocrinol 2008;158:691–8.
85. 85. Snozek CL, Chambers EP, Reading CC, Reading CC, Sebo TJ, Sistrunk JW et al. Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J Clin Endocrinol Metab 2007;92:4278–81.
86. 86. Frasoldati A, Toschi E, Zini M, Flora M, Caroggio A, Dotti C et al. Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer. Thyroid 1999;9:105–11.
87. 87. Giovanella L, Suriano S, Ceriani L, Verburg FA. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. Clin Nucl Med 2011;36:109–12.
88. 88. Lee YH, Seo HS, Suh SI, Lee NJ, Kim JH,Seol HY et al. Cut-off value for needle washout thyroglobulin in athyrotropic patients. Laryngoscope 2010;120:1120–4.
89. 89. Chung J, Kim EK, Lim H, Son EJ, Yoon JH, Youk H et al. Optimal indication of thyroglobulin measurement in fine-needle aspiration for detecting lateral metastatic lymph nodes in patients with papillary thyroid carcinoma. Head Neck 2014;36:795–801.
90. 90. Martins-Costa MC, Maciel RMB, Kasamatsu TS, Camacho CP,Ikejiri ES, Mamone MCO et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody (TgAb) measurements in needle washouts of neck lymph node biopsies in the management of patients with papillary thyroid carcinoma. ArchEndocrinol Metab 2017;61:108–14.
91. 91. Boi F, Baghino G, Atzeni F, Lai ML, Faa LG Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulatinganti-Tg antibodies. J Clin Endocrinol Metab 2006;91:1364–9.
92. 92. Jeon MJ, Kim WG, Jang EK, Choi YM, Lee YM, Sung TY et al. Thyroglobulin level in fine-needle aspirates for preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: two different cutoff values according to serum thyroglobulin level. Thyroid 2015;25:410–6.
93. 93. Giovanella L, Bongiovanni M, Trimboli P. Diagnostic value of thyroglobulin assay in cervical lymph node fine-needle aspirations for metastatic differentiated thyroid cancer. Curr Opin Oncol 2013;25:6–13.
94. 94. Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. J Clin Endocrinol Metab 2014;99:1970–62.